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Abstract
Background:  After  renal  transplant,  surgical,  infection  complications,  as  well  as  graft  rejection
may occur;  early  detection  through  non-invasive  markers  is  the  key  to  change  therapy  and  avoid
biopsy.
Objective:  The  aim  of  the  study  is  to  determine  urine  protein  proﬁles  in  patients  undergoing
renal transplant  with  complications  and  detect  its  variation  when  therapy  is  modiﬁed.
Material  and  methods:  Urine  samples  were  collected  from  patients  prior  the  transplant  and
various postoperative  stages.  Urinary  protein  proﬁles  were  obtained  by  peptide  labelling  using
isobaric isotopes  for  relative  quantiﬁcation  (iTRAQ®).
Results:  A  total  of  22  patients  were  included,  of  whom  12  developed  post-transplant  compli-
cation: 2  with  graft  rejection  (1  male  and  1  female)  and  10  (6  males  and  4  females)  in  the
group of  post-transplant  infections.  Using  iTRAQ® 15/345  and  28/113  proteins  were  identiﬁed
and fulﬁlled  the  acceptance  criteria,  in  graft  rejection  and  post-transplant  infections  group,
respectively.
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Conclusions:  Albumin  was  the  only  protein  found  in  both  groups,  the  remaining  proteins  were
different.  The  ﬁve  proteins  with  higher  scores  in  graft  rejection  were:  alpha-1-microglobulin,
5′-nucleotidase  cytosolic  III,  retinol-binding  protein  4,  membrane  protein  palmitoylated  4,  and
serine carboxypeptidase,  while  post-transplant  infections  were:  mitochondrial  acetyl-coenzyme
A synthetase,  putative  adenosyl  homocysteinase  2,  zinc  ﬁnger  protein  GLIS1,  putative  protein
FAM157B, and  zinc  ﬁnger  protein  615.  It  remains  to  elucidate  the  involvement  of  each  of  these
in patients  with  renal  transplantation.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Detección  de  proteínas  urinarias  por  iTRAQ® asociadas  a  complicaciones  del
trasplante  renal  y  su  modiﬁcación  con  la  terapia
Resumen
Antecedentes:  En  el  trasplante  renal  pueden  presentarse  complicaciones  quirúrgicas,  infec-
ciosas y  rechazo  al  injerto;  su  detección  oportuna  a  través  de  marcadores  no  invasivos  es  la
clave para  modiﬁcar  la  terapia  evitando  la  biopsia.
Objetivo:  Determinar  los  perﬁles  de  expresión  de  proteínas  urinarias  en  pacientes  con
trasplante renal  que  desarrollaron  complicaciones  y  detectar  su  variación  al  modiﬁcar  la
terapia.
Material y  métodos: Se  recolectaron  muestras  de  orina  pretrasplante  y  de  diversas  fases  del
postrasplante;  el  análisis  fue  realizado  por  marcaje  peptídico  mediante  isótopos  isobáricos  para
la cuantiﬁcación  relativa  (iTRAQ®).
Resultados:  Se  incluyeron  22  pacientes,  de  los  cuales  12  presentaron  complicaciones  en  el
postrasplante  renal:  2  con  rechazo  al  injerto  (un  hombre  y  una  mujer)  y  10  (6  hombres  y  4
mujeres) en  el  grupo  de  infecciones  sistémicas.  A  través  de  iTRAQ® se  identiﬁcaron  en  el  rechazo
al injerto  15/345  proteínas,  y  en  pacientes  con  infección,  28/113  proteínas,  que  cumplieron
los criterios  de  aceptación.
Conclusiones:  La  albúmina  fue  la  única  proteína  encontrada  en  ambos  grupos;  el  resto  de  las
proteínas  fueron  diferentes.  Las  5  proteínas  con  mayor  score  en  rechazo  al  injerto  fueron  alfa-1-
microglobulina,  5′-nucleotidasa  citosólica,  proteína  4  de  unión  a  retinol,  proteína  de  membrana
4 palmitolada  y  serín  carboxipeptidasa,  mientras  que  en  el  grupo  de  infecciones  fueron  la  acetil
coenzima  A  sintetasa  mitocondrial,  adenosil  homocisteinasa  2,  proteína  de  dedo  de  cinc  GLIS1,
proteína putativa  de  la  isoforma  FAM157B  y  proteína  de  dedo  de  cinc  615.  Queda  por  dilucidar
la participación  de  cada  una  de  estas  en  los  pacientes  con  trasplante  renal.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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enal  transplant  is  the  best  available  option  for  the  treat-
ent  of  chronic  end-stage  renal  disease,  and  compared  to
hronic  dialysis,  it  improves  quality  of  life  and  reduces  mor-
ality  for  most  patients.  The  shortage  of  organ  donations  is
his  therapy’s  greatest  limitation,  and  therefore,  extending
he  useful  life  of  renal  grafts  is  the  main  priority1,2.
Analysis  by  protocol  biopsy  of  the  transplanted  organ
s  the  method  of  choice  to  calculate  and  predict  the  risk
f  graft  failure,  providing  indications  as  to  the  possible
athogenic  mechanism  of  its  dysfunction,  and  also  serv-
ng  as  a  guide  to  the  immunosuppressive  therapy  to  be
iven3.  There  are  different  aetiological  mechanisms,  such
s  calcineurin  inhibitor  toxicity,  cellular  and  humoral  rejec-
ion,  and  infections,  which  cause  an  initial  temporary  tissue
k
o
t
iesion  with  the  ﬁnal  and  common  morphology  of  interstitial
brosis  and  tubular  atrophy4. For  this  reason,  new  diag-
ostic  approaches  are  currently  being  formulated  to  detect
nd  monitor  the  development  of  graft  dysfunction,  and  its
arious  histological  subtypes,  in  order  to  optimise  the  infor-
ation  currently  supplied  by  histology,  with  the  ultimate
oal  of  creating  a  non-invasive  tool  to  substitute  renal  graft
iopsy5,6.
Proteomics  have  been  widely  applied  in  the  search  for
arkers  for  the  diagnosis  and  prognosis  of  various  disorders.
hese  diseases  include,  cardiovascular  disease,  diseases
f  the  male  and  female  reproductive  system,  liver  and
idney  disease,  and  dialysis-related  peritonitis,  amongst
thers7--10. Other  quantitative  alternatives  with  great  poten-
ial  are  being  developed,  such  as  peptide  marking  by
sobaric  isotopes  for  relative  quantiﬁcation  (iTRAQ®),  which
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cUrinary  protein  detection  by  iTRAQ®
is  playing  a  key  role  in  quantitative  differential  expression
proteomics11.
In  this  study  we  determined  the  proﬁle  of  urinary  proteins
associated  with  renal  transplant  complications  and  assessed
their  modiﬁcation  with  speciﬁc  therapy.
Materials and methods
Study  population
This  was  an  observational,  longitudinal,  analytical  and
prospective  study,  which  included  patients  who  had  under-
gone  renal  transplant  from  a  cadaveric  donor  in  the
Hospital  Universitario  Dr.  José  Eleuterio  González,  Univer-
sidad  Autónoma  de  Nuevo  León,  during  the  period  between
28th  January  2009  and  30th  May  2013.  This  protocol  was
approved  by  our  hospital’s  Ethical  Committee  and  has  been
registered  with  the  number  HI09-003.
Patient  inclusion  criteria
Patients  over  18  years  of  age  were  included  who  had
attended  the  Transplant  Department  of  the  Hospital  Univer-
sitario  Dr.  José  Eleuterio  González  and  who  decided  to  take
part  in  the  protocol,  and  signed  the  informed  consent  form.
These  were  classiﬁed  into  two  groups:  (1)  group  of  renal
transplant  patients  with  acute  rejection,  including  patients
presenting  with  raised  creatinine  and  rejection  conﬁrmed  by
biopsy,  and  (2)  group  of  systemic  infections  with  renal  trans-
plant,  with  patients  presenting  infections  demonstrated  by
blood  culture.
Patient  exclusion  criteria
Patients  under  18  years  of  age  who  do  not  meet  the  inclusion
criteria.
Biological  sampling
The  patients  presenting  acute  rejection  were  monitored  in
the  pre-transplant  stages,  at  24,  48  and  72  h,  and  at  days  7,
15  and  30  post-transplant;  blood  samples  were  taken,  one
of  5  ml  for  serum  and  another  of  3  ml  for  blood  with  EDTA,
using  the  conventional  techniques.  The  serum  was  stored  in
1  ml  aliquots  at  −20 ◦C  until  use.
The  conventional  mid-stream  technique  was  used  for  the
urine  samples,  in  patients  with  permanent  urinary  catheters
the  sample  was  taken  by  aspirating  using  a  needle  through
the  cone  of  the  catheter;  they  were  stored  in  six  4  ml
aliquots  at  −70 ◦C  until  use.  These  samples  were  gath-
ered  in  the  pre-transplant  stages  and  every  third  day  up
to  1  month  post-transplant,  after  which  time  if  the  patient
did  not  present  complications,  they  were  discarded.  If  the
patients  presented  with  a  complication,  urine  samples  were
collected  daily  for  the  next  4  days,  and  subsequently  every
third  day  until  30  days  thereafter;  while  blood  samples  were
taken  daily  until  the  seventh  day,  and  then  every  week  for
the  next  30  days.395
etermination  of  biochemical  and  haematological
arameters
he  biochemical  tests  of  glucose  (mg/dl),  nitrogen  from
rea  (mg/dl),  creatinine  (mg/dl),  chlorine  (mmol/l),  sodium
mmol/l),  potassium  (mmol/l),  calcium  (mg/dl),  phospho-
ous  (mg/dl)  and  magnesium  (mg/dl)  were  performed  using
itros® DT60  II  Ortho  Chemistry  Clinical  Diagnostic  (DTSC
I,  Johnson  &  Johnson  Co.,  Rochester,  USA).  The  Cell  Dyn
700  (Abbott  Co.,  IL,  USA)  was  used  for  blood  cytometry,
.e.,  haemoglobin  (g/dl)  and  leukocytes  (K/l)  in  the  blood
amples  with  EDTA.
rine  analysis  by  iTRAQ®
he  urine  samples  were  analysed  in  pools  according  to  the
roup  to  which  the  patients  had  been  assigned  (graft  rejec-
ion  and  infections’  group),  2  ml  were  taken  from  each,
rom  which  4  ml  aliquots  were  made  for  each  group  and
ach  phase  of  the  study:  pre-renal  transplant  phase  (PH1),
ost-renal  transplant  phase  prior  to  complication  (PH2),
ost-renal  transplant  phase  with  complication  in  course
PH3)  and  post-renal  transplant  phase  with  post-treatment
omplication  (PH4)  for  subsequent  concentration,  precipi-
ation,  labelling  and  analysis.
.  Concentration  of  urine  samples:  an  aliquot  with  4  ml
of  urine  was  used  and  placed  in  an  Ultracel  centricon
10  kDa,  Millipore  ﬁlter;  it  was  centrifuged  at  9500  rpm  at
20 ◦C  until  reaching  a  volume  of  200  l.  One  microlitre  of
Amresco  protease  inhibitor  cocktail  was  added  and  the
sample  was  homogenised.  In  order  to  precipitate  the  pro-
teins,  2.4  ml  of  cold  acetone  at  −20 ◦C  were  added  and
they  were  left  to  precipitate  at  −20 ◦C  for  12--16  h.  The
samples  were  centrifuged  at  3500  rpm  for  15  min.  The
supernatant  was  eliminated  and  200  l  of  Milli-Q® water
added.
.  Quantiﬁcation  of  proteins:  a calibration  curve  was  pre-
pared  with  standards  of  10,  20,  30,  40  and  50  g  of
bovine  albumin.  A  Bio-Rad  protein  quantiﬁcation  kit,
based  on  Bradford’s  assay  was  used.  For  the  reduction,
alkylation,  digestion,  desalination  and  lyophilisation  of
proteins,  their  disulphide  bridges  were  reduced  with
dithiothreitol  10  mM  for  30  min  at  56 ◦C.  The  samples
were  then  incubated  with  iodoacetamide  50  mM  for
30  min  at  ambient  temperature  protected  from  the  light
to  enable  the  alkylation  of  the  cysteins.  Finally,  trypsin
(Promega,  Fitchburg,  WI,  USA)  was  added  in  a  propor-
tion  of  1:50  (enzyme:substrate).  The  enzymatic  digestion
was  incubated  for  18  h  at  37 ◦C.  Finally,  the  samples  were
desalinated  using  Sep-Pack® C18  Vac  cartridges  (Waters)
and  lyophilised  using  a Savant  SpeedVac® (Thermo  Fisher,
San  José,  CA,  USA).
. Labelling  with  the  iTRAQ® kit:  the  reagent  vials  with
isobaric  markers  114,  115,  116  and  117  were  left  at
ambient  temperature,  the  reagent  was  resuspended,
70  l of  ethanol  were  added  to  each  of  the  kit’s
reagents  and  shaken  for  1  min.  An  isobaric  marker  was
added  at  each  study  phase,  phase  PH1  was  marked
with  reagent  114,  PH2,  with  115,  PH3,  with  marker
116,  and  PH4  with  marker  117.  The  samples  and  the
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reagents  were  mixed  and  incubated  for  1  h  at  ambi-
ent  temperature.  Finally  all  the  samples  were  mixed.
The  liquid  chromatography--mass  spectrometry  system
comprised  an  Accela  micro-ﬂow  liquid  chromatograph
(Thermo  Fischer  Co.,  San  José,  CA,  USA)  with  split-
ter  (1/20)  and  an  Q-Orbitrap  VelosTM mass  spectrometer
(Thermo-Fischer  Co.,  San  José,  CA,  USA)  with  a  nano-
electrospray  ionisation  system.  The  spectrometer  was
calibrated  with  a  solution  (Calmix®)  of  10  calibrating
molecules,  which  enabled  determinations  with  accura-
cies  better  than  5  parts/million.  A  gradient  system  of
10--100%  B solvent  (acetonitrile/acetic  acid  at  0.1%)
was  used  in  the  liquid  chromatography  for  120  min
on  a  capillary  column,  PicoFrit® ProteoPepTM II  C18
75  m  ID  ×  50  mm  (New  Objective,  Inc.,  Woburn,  MA,
USA).  The  ﬂow  from  the  liquid  chromatography  system
was  400  nl/min.  Collision-induced  dissociation  and  high
energy  collision  dissociation  methods  were  used  to  frag-
ment  the  peptides.  All  the  spectros  were  acquired  in
positive  detection  mode.  The  spectrometric  data  were
analysed  against  the  human  database  using  Proteome
DiscovererTM 1.3  software,  as  SEQUEST  platform.  The
restrictive  parameters  were  set,  such  as  error  tolerance
for  the  precursor  ions  and  the  daughter  ions;  and  mod-
iﬁcations  such  as:  carbamidomethyl  cysteine,  iTRAQ®
labelling  on  the  terminal  end  and  lysines  (constant),  and
oxidation  of  methionine  (variable).
tatistical  analysis
he  biochemical  and  haematological  results  were  aver-
ged  ±  standard  deviation,  and  were  analysed  using  one-
actor  ANOVA  tests.  SPSS® version  16  software  was  used  for
his.  P  <  0.05.was  considered  statistically  signiﬁcant.
esults
n  the  study  period  48  patients  had  undergone  renal  trans-
lant  from  a  cadaveric  donor,  of  whom  22  fulﬁlled  the
nclusion  criteria  and  agreed  to  participate  in  the  protocol
fter  signing  the  informed  consent  form.
Ten  women  (45.5%)  and  12  men  (54.5%)  were  included  in
he  study,  with  an  average  age  of  45  ±  15  years  of  age.  Of  the
2  patients  included,  12  (54.5%)  presented  complications
n  the  post-renal  transplant  phase  with  an  average  age  of
3  ±  17  years  of  age;  10  (45.5%)  had  infections,  with  an
verage  age  of  43  ±  17  years  of  age,  and  2  (9%)  had  acute
ejection  and  both  patients  were  aged  63.
The  aetiology  of  the  renal  disease  of  the  patients
ith  acute  rejection  was  diabetic  nephropathy  in  both
ases  (100%),  whereas  in  the  systemic  infection  group
he  aetiologies  were:  2  (20%)  patients  with  membranous
lomerulonephritis,  2  (20%)  with  glomeruloesclerosis,  2
20%)  with  diabetic  nephropathy,  1  (10%)  with  severe  lupus
ephropathy  and  2  (20%)  of  unknown  aetiology.
Of  the  transplanted  patients  with  infections  (n  =  10),
 presented  a  surgical  complication  other  than  infection:
ne  case  with  Staphylococcus  aureus  with  arterial  pseudoa-
eurysm;  one  with  Enterococcus  faecalis  and  surgical  wound
nfection;  one  with  Staphylococcus  sp.  and  arteriovenous  ﬁs-
ula;  one  with  E.  faecalis  and  ﬁbrosis  of  the  ureter;  one
c
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ith  Pseudomonas  aeruginosa  infection  with  urinary  ﬁstula,
nd  another  case  with  Escherichia  coli  with  urinary  ﬁstula;
he  four  remaining  cases  evolved  with  no  complications  and
he  following  aetiological  agents  were  identiﬁed:  E.  coli,
lostridium  difﬁcile,  E.  faecalis  and  S.  aureus.
The  results  of  the  biochemical  and  haematological
arameters  of  each  group  of  complications  in  the  different
hases  of  the  study  are  shown  in  Table  1. In  the  case  of  the
raft  rejection  group  only  the  averages  of  the  values  are
hown,  as  there  were  only  two  cases  it  was  not  possible  to
btain  the  standard  deviation.
The  biochemical  and  haematological  parameters
ere  compared  between  the  phases  for  the  infections’
roup.  The  statistically  signiﬁcant  values  were:  glu-
ose  PH1  (184  ±  101  mg/dl)  vs.  PH2  (121  ±  41  mg/dl),
 =  0.009;  nitrogen  from  urea  PH1  (50.6  ±  28  mg/dl)  vs.  PH3
25.1  ±  8.6  mg/dl),  P  =  0.018,  and  PH1  (50.6  ±  28  mg/dl)
s.  PH4  (24.5  ±  9.8  mg/dl),  P  =  0.049;  creatinine  PH1
5.5  ±  2.9  mg/dl)  vs.  PH3  (1.7  ±  0.8  mg/dl),  P  =  0.004,
H1  (5.5  ±  2.9  mg/dl)  vs.  PH4  (1.6  ±  1.0  mg/dl),  P  =  0.013,
nd  PH2  (2.6  ±  1.7  mg/dl)  vs.  PH3  (1.7  ±  0.8  mg/dl),
 =  0.020;  and  magnesium  in  PH1  (2.1  ±  0.6  mg/dl)  vs.  PH2
1.9  ±  0.3  mg/dl),  P  =  0.050.
With  the  application  of  iTRAQ® techniques  using  liquid
hromatography--mass  spectrometry  system,  345  proteins
ere  found  in  the  graft  rejection  group,  of  which  15  met
he  acceptance  criteria  for  the  technique  (score  >  30,  2  or
ore  peptides  identiﬁed  with  95%  conﬁdence)  and  all  of
hem  were  human  peptides  (Table  2),  whereas  in  the  group
f  patients  with  infections,  113  proteins  were  found,  of
hich  28  fulﬁlled  the  acceptance  criteria  for  the  tech-
ique  (Table  3).  Differences  with  twice  the  abundance
f  proteins  between  the  study  phases  were  considered
igniﬁcant.
Of  the  15  proteins  selected  for  the  group  presenting
ith  graft  rejection,  it  was  found  that  the  serine  peptidase
nhibitor,  membrane  protein  palmitoylated  4,  serine  car-
oxypeptidase,  5′-nucleotidase  cytosolic  and  molybdopterin
ynthase  small  sub-unit  were  the  proteins  which  presented
he  highest  ratios  between  phases  PH3  and  PH4,  whereas
he  proteins  with  the  highest  score  values  were:  alpha-
-microglobulin,  5′-nucleotidase  cytosolic,  retinol-binding
rotein  4,  membrane  protein  palmitoylated  4 and  serine
arboxypeptidase  for  this  same  group.
In  the  group  of  patients  with  infections,  of  the  28  pro-
eins,  those  with  the  highest  ratios  between  phases  PH2  and
H3  were:  RNA  processing  protein  12,  glypican  4,  zinc  ﬁn-
er  protein  568,  kinase  protein  KIF13A  and  protocadherin-1;
nd  those  with  the  highest  score  were  mitochondrial  acetyl-
oenzyme  A  synthetase,  putative  adenosyl  homocysteinase
,  putative  protein  FAM157B,  zinc  ﬁnger  protein  615  and  DNA
ethyltransferase  1.
iscussion
enal  transplant  is  the  best  available  option  for  the  treat-
ent  of  end-stage  chronic  renal  disease,  and  compared  to
hronic  dialysis,  it  improves  quality  of  life  and  reduces  mor-
ality  for  the  majority  of  patients.  The  shortage  of  organ
onors  is  this  therapy’s  major  limitation,  and  therefore  the
ain  priority  is  to  extend  the  useful  life  of  renal  grafts1,2.
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Table  1  Biochemical  and  haematological  parameters  of  the  groups  in  the  four  study  phases.
Group  PH1  PH2  PH3  PH4
Haemoglobin  (g/dl) GR  11.9  9.9  9.8  10.8
GI 9.0  ±  1.4  8.6  ±  1.1  9.1  ±  1.4  9.6  ±  1.7
Leucocytes (K/l)  GR  9  4.2  4.2  7.8
GI 10.6  ±  5.4  9.2  ±  4.2  11.0  ±  5.3  10.8  ±  7.7
Glucose(mg/dl)  GR  239  97  111  513
GI 184  ±  101  121  ±  41  132  ±  64  115  ±  74
BUN (mg/dl)  GR  30.3  45.8  46.9  43.1
GI 50.6  ±  28  29.5  ±  12.8  25.1  ±  8.6  24.5  ±  9.8
Creatinine (mg/dl) GR  1.8  5.2  4.8  3.1
GI 5.5  ±  2.9 2.6  ±  1.7 1.7  ±  0.8 1.6  ±  1.0
Chlorine (mmol/l) GR  109  106  110  109
GI 105  ±  4.5  109  ±  7.1  107.4  ±  7.8  106.2  ±  6.7
Sodium (mmol/l)  GR  141  132  137  136
GI 138.1  ±  5.5  140.0  ±  3.8  136.7  ±  3.7  137.6  ±  2.9
Potassium (mmol/l)  GR  5.7  4.3  4.3  2.5
GI 4.6  ±  0.6  4.2  ±  0.7  4.5  ±  0.6  4.6  ±  0.5
Calcium (mg/dl)  GR  8.4  7.6  8.3  7.7
GI 7.8  ±  0.8  8.0  ±  0.7  8.4  ±  0.7  8.4  ±  0.6
Phosphorous  (mg/dl)  GR  2.3  5.2  6.8  4.0
GI 5.3  ±  2.6  3.1  ±  1.2  2.3  ±  0.8  2.1  ±  0.6
Magnesium (mg/dl)  GR  1.9  2.8  2.8  2.1
GI 2.1  ±  0.6  1.9  ±  0.3  2.0  ±  0.4  1.9  ±  0.4
PH1, pre-renal transplant phase; PH2, post-renal transplant phase prior to complication; PH3, post-renal transplant phase complication
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rejection.
New  non-invasive  diagnostic  approaches  are  currently
being  developed  to  detect  and  monitor  the  evolution  of
graft  dysfunction9--11;  proteomics  have  been  widely  used  to
look  for  markers  for  the  diagnosis  and  prognosis  of  various
diseases10,12--14.  Other  quantitative  alternatives  with  great
potential  have  been  developed  recently,  such  as  iTRAQ®,
which  is  playing  an  important  role  in  quantitative  differen-
tial  expression  proteomics.  It  is  predicted  that  proteomics
will  play  a  major  part  in  the  area  of  nephrology  in  the
short  term,  and  that  this  progress  will  require  interactive
dialogue  and  collaboration  between  clinical  and  analytical
specialists15,16.
In this  study  we  describe  a  series  of  proteins  associated
with  various  post  renal  transplant  complications,  such  as
graft  rejection  and  infections,  and  the  modiﬁcation  of  these
proteins  with  the  therapy  speciﬁc  to  each  of  them.  This
study  is  the  ﬁrst  in  our  country  to  describe  the  proteins  which
are  altered  in  renal  transplant  patients  who  go  on  to  reject
the  graft,  and  in  those  who  present  infectious  complications.
By  labelling  using  the  iTRAQ® technique  and  ﬁnal  anal-
ysis  by  liquid  chromatography--mass  spectrometry,  a  total
of  345  proteins  were  found  in  the  graft  rejection  group,  of
which  only  15  met  the  acceptance  criteria  described  above
(Table  2).  While  in  the  group  of  patients  with  infections,
28  of  the  113  proteins  identiﬁed  fulﬁlled  the  technique’s
acceptance  criteria  (Table  3).
Of  the  15  proteins  found  in  the  graft  rejection  group,
the  ﬁve  presenting  the  highest  ratios  between  phases
PH3  and  PH4  were:  serine  peptidase  inhibitor  which  is
activated  in  response  to  cellular  stress  and  during  renal
ischaemia-reperfusion  injury17,18,  likewise,  it  has  been
p
w
w
troup of patients with infection; GR, group of patients with graft
eported  that  levels  of  the  inhibitor  correlate  with  the
everity  of  the  rejection,  it  being  possible  to  predict  the
ubsequent  function  of  the  renal  allograft19,20;  membrane
rotein  palmitoylated  4,  an  integral  membrane  protein
ith  guanylate  kinase  activity,  which  allows  it  to  interact
ith  the  cytoskeleton  and  regulate  cell  proliferation  and
ignal  transduction21;  serine  carboxypeptidase,  a  protease
f  unknown  function  which  was  ﬁrst  classiﬁed  in  human
acrophages,  believed  to  be  limited  to  a great  extent  to
he  monocytic  strain,  although  recent  studies  demonstrate
hat  it  might  also  be  expressed  by  cells  outside  the  immune
ystem22;  5′-nucleotidase  cytosolic,  which  is  involved  in  var-
ous  functions,  such  as  cell--cell  communication,  nucleic
cid  repair,  synthesis  of  nucleotides,  signal  transduction  and
embrane  transport23,  and  ﬁnally,  molybdopterin  synthase
mall  sub-unit,  which  in  humans  is  involved  in  the  biosynthe-
is  of  molybdenum  cofactor,  a  genetic  deﬁciency  that  results
n  autosomal  recessive  disease  which  is  generally  fatal  with
evere  neurological  symptoms24.  The  highest  ratios  between
hases  PH3  vs.  PH4  of  these  ﬁve  proteins  show  that  they  are
seful  candidates  as  biomarkers  of  poor  renal  graft  function.
oreover,  it  can  be  seen  that  in  PH4,  with  the  modiﬁcation
f  immunosuppressive  therapy,  the  expression  of  these  ﬁve
roteins  is  signiﬁcantly  reduced,  demonstrating  their  use-
ulness  as  potential  biomarkers  of  good  renal  graft  function
n  response  to  immunosuppressive  therapy.
Furthermore,  for  this  same  group  of  patients,  the  ﬁve
roteins  with  the  highest  score  were:  alpha-1-microglobulin,
hich  is  a  lipocalin  with  immunosuppressive  properties25,
hich  eliminates  free  radicals26, and  is  one  of  the  pro-
eins  that  has  been  most  studied  as  a  potential  non-invasive
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Table  2  Proteins  in  the  group  of  patients  with  graft  rejection  who  fulﬁlled  the  acceptance  criteria.
No.  Protein  PH2/PH1;
PH1/PH2
PH3/PH2;
PH2/PH3
PH4/PH3;
PH3/PH4
PH4/PH2;
PH2/PH4
PH4/PH1
PH1/PH4
1  Albumin  0.469;  2.1  2.2;  0.456  0.039a;  25.6a 0.070a;  14.3a 0.039a
25.6*a
2  Alpha-1-microglobulin  NS  2.443;  0.409  0.062a;  16.26a 0.067a;  15.01a 0.044a
22.52a
3  5′-nucleotidase  cytosolic
III
0.360;  2.78  2.34;  0.428  0.035a;  28.26a 0.045a;  22.44a 0.038a
26.1a
4  Retinol-binding  protein  4  0.404;  2.48  2.77;  0.36  0.049a;  20.49a 0.049a;  20.56a 0.035a
28.73a
5  Membrane  protein
palmitoylated4
NS  2.1;  0.48 0.026a;  38.22a 0.054a;  18.66a 0.041a
24.57a
6  Serine  carboxypeptidase  0.35;  2.79  2.36;  0.42  0.033a;  30.17a 0.091a;  10.99a 0.033a
20.17a
7  Ribosomal  protein
assembly
0.36;  2.20  2.36;  0.42  0.04a;  24.85a 0.02a;  53.98a 0.039a
25.77a
8  Molybdopterin  synthase
small  sub-unit
0.36;  2.78  2.35;  0.43  0.095a;  10.50a 0.17a;  5.86a 0.07a
15.15a
9  Serine  peptidase  inhibitor  0.46;  2.17  2.02;  0.49  0.02a;  60.48a 0.03a;  31.79a 0.015a
64.68a
10  Serine-threonine  kinase  2  0.43;  2.32  2.24;  0.45  0.046a;  21.68a 0.091a;  11.00a 0.036a
27.43a
11  N-acetyl  galactosamine
transferase  10
0.43;  2.33  3.08;  0.32  NR  NR  NR
12 Polycistin-1  0.46;  2.19  3.08;  0.325  NR  NR  NR
13 Alpha-1-acid  glycoprotein
(orosomucoid)
0.42;  2.36  2.40;  0.417  NR  NR  NR
14 Hypothetical  protein
LOC91750
0.52;  1.92 2.36;  0.423  NR  NR  NR
15 GTPase-activating  protein  0.443;  2.26  2.67;  0.38  0.056;  17.89  0.17;  6.05  0.07
14.77
PH1, pre-renal transplant phase; PH2, post-renal transplant phase prior to complication; PH3, post-renal transplant phase complication
in course; PH4, post-renal transplant phase complication treated; GI, group of patients with infection; GR, group of patients with graft
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erejection; NT, not taken; NS, not signiﬁcant.
a > 5 times raised.
iomarker  for  the  early  detection  of  kidney  abnormalities,
s  well  as  for  its  usefulness  in  differentiating  nephrolog-
cal  and  urological  diseases27;  5′-nucleotidase  cytosolic,
hose  pharmacological  inhibition  has  been  reported  to
ncrease  CAM  concentrations  and  improve  renal  function  in
at  experimental  models  of  ischaemia  and  reperfusion28;
etinol-binding  protein  4,  which  has  been  reported  as  raised
n  patients  with  interstitial  tubular  injury29 and  is  secreted
y  the  adipocytes,  and  has  been  reported  as  raised  in
ases  of  insulin  resistance30;  membrane  protein  palmitoy-
ated  4,  which  has  been  seen  over-expressed  in  renal  tissue
ubjected  to  ischaemia-reperfusion  processes31,  and  serine
arboxypeptidase,  which  is  particularly  expressed  in  the
eart  and  kidneys22.  Similar  to  several  publications  on  renal
unction,  we  found  in  this  study  that  these  ﬁve  proteins  are
ver-expressed  during  the  episode  of  acute  graft  rejection
nd  their  expression  is  signiﬁcantly  low  when  the  patients
re  not  presenting  renal  graft  rejection  or  are  responding  to
he  modiﬁcation  made  to  their  immunosuppressive  therapy.
In  the  group  of  patients  with  infections,  of  the  28
roteins,  those  which  presented  the  highest  ratios  between
hases  PH2  vs.  PH3  were:  RNA  processing  protein  12;
w
o
f
wlypican  4,  of  the  heparan  sulphate  proteoglycans  family
f  the  cell  surface  which  express  in  a  regulated  manner
y  developing  a  speciﬁc  tissue32;  zinc  ﬁnger  protein  568,
hich  has  been  described  as  having  a  protective  effect
n  various  stress  conditions,  such  as  thermal  shock  and
smotic  shock33; kinase  protein  KIF13A,  which  are  proteins
f  the  kinase  superfamily,  that  are  protagonists  in  the
ntracellular  transport  system,  which  is  essential  for  cell
unction  and  morphology34;  and  protocadherin-1  protein,
 protein  family  which  it  has  been  suggested  plays  a  role
n  brain  development,  glomerular  cleft  formation,  and  can
lso  act  as  tumour  suppressors,  although  their  mechanisms
f  action  have  not  been  explained35.
The  proteins  with  the  highest  score  for  this  group  with
nfections  were:  isoform  3  of  mitochondrial  acetyl-
oenzyme  A  synthetase,  described  as  important  in
aintaining  normal  body  temperature  during  fasting,  and
nergy  homeostasis36; putative  adenosyl  homocysteinase  2,
hose  expression  increases  considerably  during  activation
f  blood  and  skin  cells37; putative  protein  FAM157B,  whose
unction  has  not  been  reported;  zinc  ﬁnger  protein  615,
hich  participates  in  transcription  regulation38, and  DNA
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Table  3  Proteins  in  the  group  of  patients  with  infections  which  fulﬁl  the  acceptance  criteria.
No.  Proteins  PH2/PH1;
PH1/PH2
PH3/PH2;
PH2/PH3
PH4/PH3;
PH3/PH4
PH3/PH1;
PH1/PH3
PH4/PH2;
PH2/PH4
PH4/PH1;
PH1/PH4
1  Albumin  0.04a;
23.50a
14.77a;
0.07a
NS  0.370;  2.70  8.67a;  0.12a 0.21;  4.68
2 Protein  product  with  no
name
0.04a;
19.35a
7.19a;  0.14a NS  0.281;  3.56  11.16;  0.09  0.43;  2.32
3 Acetyl-coenzyme  A
synthetase
0.05a;
19.35a
5.89a;  0.17a NS  0.281;  3.55  3.92;  0.26  0.19a;  5.24a
4  Adenosylhomocysteinase  2  0.10a;
10.00a
4.24;  0.24  NS  0.380;  2.64  2.97;  0.34  0.26;  3.85
5 Zinc  ﬁnger  protein  GLIS1 0.09a;
11.06a
NS  NS  0.397;  2.52 3.20;  0.31  0.24;  4.26
6 Putative  protein  FAM157B  0.16a;  6.43a 2.16;  0.46  0.380;  2.63  0.394;  2.54  NR  0.16a;  6.14a
7  Zinc  ﬁnger  protein  615  0.02a;
44.08a
12.23a;
0.08a
NS  0.25;  3.97  12.68a;
0.08a
0.24;  4.16
8 DNA  methyltransferase  1  0.03a;
30.01a
9.16a;  0.11a NS  0.26;  3.79  4.00;  0.25  0.14a;  7.05a
9  Armadillo  repeat  protein  5  NR  NR  NS  NS  NR  0.33;  3.02
10 Zinc  ﬁnger  protein  629  0.04a;
27.91a
9.98a;  0.10a NS  0.36;  2.79  5.40a;  0.18a 0.18a;  5.46a
11  AT  DNA  binding  protein  0.07;  13.28  4.71;  0.21  NS  0.33;  3.04  3.64;  0.27  0.24;  4.14
12 Protein  product  with  no
name
0.06a;
15.80a
6.95a;  0.14a NS  0.29;  3.40  6.62a;  0.15a 0.30;  3.33
13 Inmunoglobulin  lambda  0.04a;
26.38a
9.93a;  0.10a NS  0.39;  2.56  7.60a;  0.13a 0.25;  4.02
14 Protein  product  with  no
name
0.02a;
56.77a
19.83a;
0.05a
0.48;  2.09  0.38;  2.89  9.88a;  0.10a 0.16a;  6.34a
15  Ecotropic  viral  integration
protein  5
0.06a;
16.37a
4.84;  0.21 NS  0.29;  3.43  5.44a;  0.18a 0.32;  3.11
16 Cell  cycle  progression
protein  1
NR  NR  NS  0.36;  2.81  NR  0.28;  5.31
17 Atropine-1  0.06a;
18.15a
7.20a;  0.14a 0.46;  2.18  0.42;  2.36  6.33a;  0.16a 0.26;  3.92
18 Zinc  ﬁnger  protein  568  NR  32.64a;
0.03a
NS  0.26;  3.79  37.02a;
0.03a
0.28;  3.53
19 Protocadherin-1  0.04a;
26.83a
16.37a;
0.06a
NS  0.43;  2.31  14.16a;
0.07a
0.31;  3.24
20 GTPase-activating  protein  0.12a;  8.42a 11.04a;
0.09a
NS  NS  10.52a;
0.09a
NS
21 Gene  19  amyotrophic
lateral  sclerosis  protein
0.02a;
40.10a
18.38a;
0.05a
NS  0.43;  2.31  11.69a;
0.09a
0.36  2.8
22 Beta-2-microglobulin  0.01a;
91.65a
25.7a;  0.04a NS  0.28;  3.57  20.4a;  0.05a 0.22;  4.49
23 Kinase  protein  KIF13A  0.02a;  51.2a 54.72a;
0.02a
0.39;  2.54  0.38;  2.64  13.07a;
0.08a
0.35;  2.88
24 Protocadherin-1  0.04a;
26.83a
16.37a;
0.06a
NS  0.43;  2.31  14.16a;
0.07a
0.31;  3.24
25 GTPase-activating  protein  0.12a;  8.42a 11.04a;
0.09a
NS  NS  10.52a;
0.09a
NS
26 Gene  19  amyotrophic
lateral  sclerosis  protein
0.02a;
40.10a
18.38a;
0.05a
NS  0.43;  2.31  11.69a;
0.09a
0.36;  2.8
27 Beta-2-microglobulin  0.01a;
91.65a
25.7a;  0.04a NS  0.28;  3.57  20.4a;  0.05a 0.22;  4.49
28 Kinase  protein  KIF13A  0.02a;  51.2a 54.72a;
0.02a
0.39;  2.54  0.38;  2.64  13.07a;
0.08a
0.35;  2.88
PH1, pre-renal transplant phase; PH2, post-renal transplant phase prior to complication; PH3, post-renal transplant phase complication
in course; PH4, post-renal transplant phase complication treated; GI, group of patients with infection; GR, group of patients with graft
rejection; NT, not taken; NS, not signiﬁcant.
a > 5 times raised.
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200  
ethyltransferase  1,  which  participates  in  the  regulation
f  gene  expression  according  to  a  methylation  pattern39.
Furthermore,  massive  proteinuria  has  been  recognised  as
 risk  factor  for  graft  failure  in  the  long  term40.  A  recent
tudy  indicated  that  low-grade  proteinuria  was  a  strong  pre-
ictor,  irrespective  of  graft  failure  long  term41.  In  this  study,
lbumin  was  expressed  in  the  two  complications  evaluated,
herefore  it  was  not  useful  as  a  speciﬁc  biomarker  of  any
f  the  complications  studied,  but  it  is  an  indicator  of  renal
amage,  as  it  is  one  of  the  proteins  which  are  most  expressed
rior  to  transplant;  therefore  when  the  transplant  is  per-
ormed,  its  expression  diminishes  considerably,  but  if  any
ype  of  complication  presents,  it  over-expresses  again.
As  described  in  this  study,  various  proteins  are  candidates
s  biomarkers  of  good  renal  graft  function,  since  their  pres-
nce  in  the  urine  can  be  used  to  distinguish  the  patients
ho  have  good  graft  function  from  those  who  do  not.  Fur-
hermore,  each  of  the  complications  assessed  presented  a
eries  of  different  proteins,  apart  from  albumin.  This  study
mphasizes  the  usefulness  of  urinary  proteomics  in  identify-
ng  biomarkers  and  in  the  future  design  of  a  non-invasive
iagnostic  tool  to  better  detect  transplanted  renal  graft
ysfunction.
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